These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 19309723)

  • 1. Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.
    Vidal L; Tsao MS; Pond GR; Cohen EE; Cohen RB; Chen EX; Agulnik M; Hotte S; Winquist E; Laurie S; Hayes DN; Ho J; Dancey J; Siu LL
    Head Neck; 2009 Aug; 31(8):1006-12. PubMed ID: 19309723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
    Agulnik M; Cohen EW; Cohen RB; Chen EX; Vokes EE; Hotte SJ; Winquist E; Laurie S; Hayes DN; Dancey JE; Brown S; Pond GR; Lorimer I; Daneshmand M; Ho J; Tsao MS; Siu LL
    J Clin Oncol; 2007 Sep; 25(25):3978-84. PubMed ID: 17761983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of gefitinib in patients with advanced salivary gland cancers.
    Jakob JA; Kies MS; Glisson BS; Kupferman ME; Liu DD; Lee JJ; El-Naggar AK; Gonzalez-Angulo AM; Blumenschein GR
    Head Neck; 2015 May; 37(5):644-9. PubMed ID: 24585506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.
    Finn RS; Press MF; Dering J; Arbushites M; Koehler M; Oliva C; Williams LS; Di Leo A
    J Clin Oncol; 2009 Aug; 27(24):3908-15. PubMed ID: 19620495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
    Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
    J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas.
    Suzuki S; Dobashi Y; Minato H; Tajiri R; Yoshizaki T; Ooi A
    Virchows Arch; 2012 Sep; 461(3):271-82. PubMed ID: 22828828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.
    Galsky MD; Von Hoff DD; Neubauer M; Anderson T; Fleming M; Nagarwala Y; Mahoney JM; Midwinter D; Vocila L; Zaks TZ
    Invest New Drugs; 2012 Apr; 30(2):695-701. PubMed ID: 20857170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
    Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.
    Lee MJ; Kim N; Choung HK; Choe JY; Khwarg SI; Kim JE
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):125-33. PubMed ID: 26141290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
    Varella-Garcia M; Mitsudomi T; Yatabe Y; Kosaka T; Nakajima E; Xavier AC; Skokan M; Zeng C; Franklin WA; Bunn PA; Hirsch FR
    J Thorac Oncol; 2009 Mar; 4(3):318-25. PubMed ID: 19247083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis.
    Ettl T; Stiegler C; Zeitler K; Agaimy A; Zenk J; Reichert TE; Gosau M; Kühnel T; Brockhoff G; Schwarz S
    Hum Pathol; 2012 Jun; 43(6):921-31. PubMed ID: 22154363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma.
    Rettig EM; Tan M; Ling S; Yonescu R; Bishop JA; Fakhry C; Ha PK
    Laryngoscope; 2015 Sep; 125(9):E292-9. PubMed ID: 25963073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
    Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
    Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.
    Scaltriti M; Chandarlapaty S; Prudkin L; Aura C; Jimenez J; Angelini PD; Sánchez G; Guzman M; Parra JL; Ellis C; Gagnon R; Koehler M; Gomez H; Geyer C; Cameron D; Arribas J; Rosen N; Baselga J
    Clin Cancer Res; 2010 May; 16(9):2688-95. PubMed ID: 20406840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
    Falchook GS; Lippman SM; Bastida CC; Kurzrock R
    Head Neck; 2014 Mar; 36(3):E25-7. PubMed ID: 23852769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands.
    Gibbons MD; Manne U; Carroll WR; Peters GE; Weiss HL; Grizzle WE
    Laryngoscope; 2001 Aug; 111(8):1373-8. PubMed ID: 11568571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.
    Williams MD; Roberts DB; Kies MS; Mao L; Weber RS; El-Naggar AK
    Clin Cancer Res; 2010 Apr; 16(8):2266-74. PubMed ID: 20371674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer.
    Ettl T; Baader K; Stiegler C; Müller M; Agaimy A; Zenk J; Kühnel T; Gosau M; Zeitler K; Schwarz S; Brockhoff G
    Br J Cancer; 2012 Feb; 106(4):719-26. PubMed ID: 22240798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas.
    Clauditz TS; Reiff M; Gravert L; Gnoss A; Tsourlakis MC; Münscher A; Sauter G; Bokemeyer C; Knecht R; Wilczak W
    Pathology; 2011 Aug; 43(5):459-64. PubMed ID: 21670724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.